Thrive Earlier Detection, headquartered in Cambridge, Massachusetts, closed on a Series B financing worth $257 million.
Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.
With $76 million in financing, San Diego-based Autobahn Therapeutics is hitting the ground with a goal of developing regenerative medicines aimed at treating disorders of the central nervous system (CNS).
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Seattle-based Athira Pharma closed on a Series B financing worth $85 million, led by Perceptive Advisors.
U.K.-based NodThera is building up the company’s war chest to develop therapies for diseases driven by chronic inflammation, securing $55 million in Series B financing.
Vancouver, British Columbia-based AbCellera closed a Series B financing worth $105 million, led by OrbiMed and DCVC Bio.
Two years after Boston-based HotSpot Therapeutics launched, the company secured $65 million in Series B funding to advance the development of allosteric therapies that target “regulatory hotspots” in the body into the clinic.
Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance the company’s vaccine and immunotherapy candidates.
Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.